Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Avishai Samouha"'
Publikováno v:
Cancer Management and Research
Elisha J Fogel,1 Avishai Samouha,1 Sanjay Goel,2 Radhashree Maitra1,2 1Department of Biology, Yeshiva University, New York, NY, 10033, USA; 2Albert Einstein College of Medicine at Montefiore Medical Center, Bronx, NY, 10461, USACorrespondence: Radhas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16e6ea9310a2b1a425012d4f71d36596
https://doi.org/10.2147/cmar.s324203
https://doi.org/10.2147/cmar.s324203
Publikováno v:
J Oncol Res Ther
BACKGROUND: Approximately 45% of individuals diagnosed with Colorectal Cancer (CRC) also possess KRAS mutations. One developing therapeutic method for this disease is reovirus treatment. It is theorized that reovirus treatment on patients with KRAS m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c071eabfc1193b85b8aaa73b925e48a4
https://pubmed.ncbi.nlm.nih.gov/34841205
https://pubmed.ncbi.nlm.nih.gov/34841205
Publikováno v:
Cancer Research. 81:2148-2148
Introduction: Reovirus propagates with high efficiency in KRAS mutated colorectal cancer (CRC). About 40-45% of CRC patients possess KRAS mutation. Oncolytic reovirus treatment in combination with chemotherapy was tested in patients possessing KRAS m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89dbdd1c8ab2426f6bc9b69295ac183e
https://doi.org/10.1158/1538-7445.am2021-2148
https://doi.org/10.1158/1538-7445.am2021-2148